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Abstract
Serine protease granzyme B plays important roles in infections, autoimmunity, transplant rejection, and antitumor
immunity. A triple-mutated granzyme B variant that encodes three amino substitutions (Q48R, P88A, and Y245H) has been
reported to have altered biological functions. In the polymorphism rs8192917 (2364A.G), the A and G alleles represent wild
type QPY and RAH mutant variants, respectively. In this study, we analyzed the impact of granzyme B polymorphisms on
transplant outcomes in recipients undergoing unrelated HLA-fully matched T-cell-replete bone marrow transplantation
(BMT) through the Japan Donor Marrow Program. The granzyme B genotypes were retrospectively analyzed in a cohort of
613 pairs of recipients with hematological malignancies and their unrelated donors. In patients with myeloid malignancies
consisting of acute myeloid leukemia and myelodysplastic syndrome, the donor G/G or A/G genotype was associated with
improved overall survival (OS; adjusted hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.41–0.89; P=0.01) as well as
transplant related mortality (TRM; adjusted HR, 0.48; 95% CI, 0.27–0.86, P=0.01). The recipient G/G or A/G genotype was
associated with a better OS (adjusted HR, 0.68; 95% CI, 0.47–0.99; P=0.05) and a trend toward a reduced TRM (adjusted HR,
0.61; 95% CI, 0.35–1.06; P=0.08). Granzyme B polymorphism did not have any effect on the transplant outcomes in patients
with lymphoid malignancies consisting of acute lymphoid leukemia and malignant lymphoma. These data suggest that
there is an association between the granzyme B genotype and better clinical outcomes in patients with myeloid
malignancies after unrelated BMT.
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Introduction
Hematopoietic stem cell transplantation (HSCT) represents the
only potentially curative option for many malignant conditions.
Although substantial improvements in the supportive care of
transplanted patients have been achieved in recent years, the
profound compromise in the immune system associated with
HSCT constitutes a significant risk for life threatening complica-
tions including GVHD, severe infections and disease relapse.[1]
HLA matching represents the major genetic determinant in
clinical outcomes after allogeneic HSCT, however, several studies
have suggested that non-HLA genes associated with immune
functions are also involved in determining the clinical outcome.[2]
Single nucleotide polymorphisms (SNPs) in genes involved in the
immune response to infections and inflammatory reactions have
been identified as additional predictive markers of clinical
outcomes in HSCT.[3,4,5,6,7,8,9,10,11,12,13,14]
Following HSCT, cytotoxic T lymphocytes (CTLs) and natural
killer (NK) cells, mainly derived from the donor, constitute the
most important effector cells that eliminate allogeneic cells,
including malignant cells, virus-infected cells and healthy cells.
The destruction of the target cells occurs by at least one of the
three defined mechanisms: TNF-a release, the Fas/Fas ligand
interaction, and the granzyme/perforin pathway.[15] The later
has been postulated as being the predominant mechanism for
immune-mediated apoptosis of allogeneic cells.[16,17]
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23827Granzyme B, the most abundant serine protease stored in
secretory granules of CTLs and NK cells, is released upon target
cell recognition, then specifically enters into the target cell
cytoplasm via perforin, finally leading to target cell lysis.[15]
Although the induction of target cell death by its pro-apoptotic
properties has been considered the central function of granzyme B,
growing evidence indicates that this protease also possesses
additional non-death-related functions. These non-classical or
extracellular functions are perforin-independent mechanisms and
include immunosuppression, receptor cleavage, and cytokine-like
effects.[15,18,19] Initially believed to be expressed exclusively by
NK cells and CTLs, recent reports have shown that granzyme B
can be expressed by various additional cell types, such as mast
cells, neutrophils, dendritic cells (DCs), B cells, keratinocytes,
chondrocytes, and vascular smooth muscle cells.[20,21,22,23,24]
Granzyme B is involved in the pathophysiology of viral and
bacterial infections, solid organ rejection, autoimmune diseases,
and antitumor immunity.[25,26,27,28,29,30] In the granzyme B
gene, a triple-mutated allele (Q48R, P88A, and Y245H) in strong
linkage disequilibrium is found in European, African, and Asian
populations, including the Japanese population, at an allelic
frequency of 25–30%.[31,32] The biological and functional
relevance of the RAH mutant granzyme B, however, still remains
controversial. Although it was reported that the RAH variant was
incapable of inducing apoptosis,[31] and cdT cells derived from
donors possessing the RAH variant had impaired cytotoxicity
against target cells;[33] other studies have reported that RAH
mutant granzyme B displays normal proteolytic and cytotoxic
properties[34] and the cytotoxicic activity of T lymphocytes did
not differ among donors with QPY or RAH genotypes.[32]
In this study, we hypothesized that a defect of inducing
apoptosis in mutant granzyme B could influence the clinical
outcomes of HSCT. To test this hypothesis, we investigated the
influence of the QPY/RAH variants on the clinical outcomes after
HSCT. Because these variants are in clear linkage disequilibrium,
the study was focused on genotyping the polymorphism rs8192917
(2364A.G) in the granzyme B gene, which results in Q48R
variants, and analyzed its impact on the clinical outcomes of
patients undergoing allogeneic bone marrow transplantation
(BMT) using an HLA allele-matched unrelated donor. The data
herein show that the donor G/G or A/G allele, which represents
mutant granzyme B, is associated with a significantly improved
overall survival (OS) and reduced transplant-related mortality
(TRM) in patients with myeloid malignancies.
Methods
Patients
Granzyme B genotyping was performed on 613 recipients with
hematological malignancies and their unrelated donors who
underwent BMT through the Japan Marrow Donor Program
(JMDP) with T-cell-replete marrow from HLA-A, -B, -C, -DRB1,
-DQB1, and -DPB1 allele-matched donors between January 1993
and December 2007. The HLA genotypes of patients and donors
were determined by the Luminex microbead method, as described
previously (Luminex 100 System; Luminex, Austin, TX).[35,36]
Although the Luminex microbead method does not provide
unambiguous HLA 4-digit typing for all genotypes, the JMDP has
confirmed that this method can identify all HLA alleles with
.0.1% frequency among the Japanese population.[37]
None of the present patients had a history of any prior
transplantation. The final clinical survey of these patients was
completed by November 1, 2008. The diagnoses were acute
myeloid leukemia (AML) in 240 (39%), acute lymphoblastic
leukemia (ALL) in 170 (28%), myelodysplastic syndrome (MDS) in
113 (18%), and malignant lymphoma (ML) in 90 (15%; Tables 1
and 2). The recipients were defined as having standard risk
disease if they had AML or ALL in the first complete remission,
ML in any complete remission, or MDS. All others were
designated as having high-risk disease. The myeloid malignancies
include AML and MDS, and the lymphoid malignancies included
ALL and ML. Cyclosporine- or tacrolimus-based regimens were
used in all patients for GVHD prophylaxis, and anti-T cell
therapy, such as anti-thymocyte globulin and ex vivo T cell
depletion were not in any of the patients. All patients and donors
gave their written informed consent at the time of transplantation
to participate in molecular studies of this nature according to the
declaration of Helsinki. This project was approved by the
Institutional Review Board of Kanazawa University Graduate
School of Medicine and the JMDP.
Granzyme B genotyping
Genotyping of granzyme B was performed using the TaqMan-
Allelic discrimination method in a StepOne Plus Real Time PCR
system (Applied Biosystems, Foster City, CA, USA), and the results
Table 1. Donor and recipient characteristics (first part).
Variable No. Ratio
No. of cases 613
Recipient age, years
Median 36
Range 1–70
Donor age, years
Median 34
Range 20–57
Year of transplant
Median 2002
Range 1993–2007
Recipient Granzyme B genotype
G/G 30 5%
A/G 202 33%
A/A 381 62%
Donor Granzyme B genotype
G/G 27 4%
A/G 194 32%
A/A 392 64%
Recipient sex
Male 383 62%
Female 230 38%
Donor sex
Male 402 66%
Female 210 34%
Missing 1 0%
Donor/recipient sex
Sex matched 409 67%
Female/male 92 15%
Male/female 111 18%
Missing 1 0%
doi:10.1371/journal.pone.0023827.t001
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(Applied Biosystems). The genotyping assay was conducted in 96-
well PCR plates. The amplification reaction contained template
DNA, TaqMan universal master mix and the specific probe
designed for SNP rs8192917 (2364A.G) of granzyme B (product
No. C_2815152_20 ; Applied Biosystems).
Data management and statistical analysis
The data were collected by the JMDP using a standardized
report form. Follow-up reports were submitted at 100 days, 1 year
and annually after transplantation. The pre-transplant cytomeg-
alovirus (CMV) serostatus was routinely tested for only patients,
but not the donors. Engraftment was confirmed by an absolute
neutrophil count of more than 0.5610
9/L for at least 3
consecutive days. On collecting data, acute and chronic GVHD
were diagnosed and graded using the previous criteria[38,39] and
data using updated criteria for assessment of GVHD[40,41] were
not available in our cohort. The OS was defined as the number of
days from transplantation to death from any cause. Disease relapse
was defined as the number of days from transplantation to disease
relapse. TRM was defined as death without relapse. Any patients
who were alive at the last-follow-up date were censored. The data
about causative microbes of infections and postmortem changes in
cause of death, as well as the data on supportive care, including
prophylaxis for infections and therapy for GVHD, which were
given on an institutional basis, were not available for this cohort.
The analysis was performed using the Excel 2007 (Microsoft
Corp, Redmond, WA, USA) and modified R (The R Foundation
for Statistical Computing, Perugia, Italy) software pro-
grams.[42,43] The probability of overall survival (OS) was
calculated using the Kaplan-Meier method and compared using
the log-rank test. The probabilities of TRM, disease relapse, acute
GVHD, chronic GVHD, and engraftment were compared using
the Grey test[44] and analyzed using the cumulative incidence
analysis,[42] considering relapse, death without disease relapse,
death without acute GVHD, death without chronic GVHD, and
death without engraftment as respective competing risks. The
variables were recipient age at time of transplantation, sex,
pretransplant CMV serostatus, disease characteristics (disease
type, disease lineage and disease risk at transplantation), donor
characteristics (age, sex, sex compatibility, and ABO compatibil-
ity), transplant characteristics (conventional or reduced-intensity
conditioning,[45] total body irradiation-containing regimen,
tacrolimus versus cyclosporine, and total nucleated cell count
harvested per recipient weight [TNC]), and the year of
transplantation. The median was used as the cutoff point for
continuous variables. The chi-square test and Mann-Whitney U
test were used to compare two groups. The Hardy-Weinberg
equilibrium for the granzyme B gene polymorphism was tested
using the Haploview software program.[6]
Multivariate Cox models were used to evaluate the hazard ratio
associated with the granzyme B polymorphism. Covariates found
to be P#0.10 in the univariate analyses were used to adjust the
hazard ratio. The covariates were selected according to myeloid
and lympoid malignancies.
For both the univariate and multivariate analyses, P values were
two sided, and outcomes were considered to be significant for
P#0.05.
Results
The frequencies of the granzyme B genotypes
Granzyme B gene polymorphism was analyzed in 613 unrelated
bone marrow donor-transplant recipient pairs (Tables 1 and 2).
The genotype frequencies of G/G, A/G and A/A were 5%, 33%
and 62% in recipients and 4%, 32% and 64% in donors. These
were similar to HapMap data in the Japanese (9%, 29% and 62%,
respectively) and European (5%, 35% and 60%, respectively)
populations, and thus were in accord with the Hardy-Weinberg
equilibrium (P=0.79).
Transplant outcome according to the granzyme B
genotype
The median follow-up duration in the cohort was 55 months
among the survivors (range 4 to 168 months), and 191 recipients
(31%) had relapsed or progressed, and 309 (50%) had died.
Eighteen patients (3%) died before engraftment. The donor and
recipient granzyme B genotype did not significantly influence the
cumulative incidence of engraftment (data not shown).
The transplant outcomes according to the granzyme B genotype
are summarized in Table 3. Patients with myeloid malignancies,
which included AML and MDS, who received transplants from
donors with the G/G or A/G genotype had a significantly better
5-year OS (58% vs. 42%, P=0.01; Fig. 1A) and a trend toward
lower 5-year relapse rate (27% vs. 36%, P=0.09) than those
receiving transplants from donors with the A/A genotype. No
Table 2. Donor and recipient characteristics (second part).
Variable No. Ratio
Disease
Acute myeloid leukemia 240 39%
Myelodysplastic syndrome 113 18%
Acute lymphoblastic leukemia 170 28%
Malignant lymphoma 90 15%
Disease stage
Standard risk 357 58%
High risk 256 42%
ABO matching
Major or/and minor mismatch 246 40%
Major mismatch 136 22%
Minor mismatch 126 21%
Bidirectional 18 3%
Missing 7 1%
Conditioning regimen
Myeloablative 499 81%
Reduced intensity 114 19%
With total body irradiation 472 77%
Pretransplant CMV serostatus
CMV positive recipient 440 72%
Missing 70 11%
GVHD prophylaxis
With cyclosporine 296 48%
With tacrolimus 314 51%
Missing 3 0%
TNC, 610
8 per kg
Median 4.9
Range 0.1–79.1
Abbreviations: TNC: total nucleated cell count harvested.
doi:10.1371/journal.pone.0023827.t002
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GVHD in relation to the donors’ polymorphism status. A
comparison between the donor G/G and A/G genotypes showed
no significant difference in OS (71% vs. 56%, P=0.36), TRM (6%
vs. 23%, P=0.36), or the relapse rate (30% vs. 26%, P=0.65).
When patients with AML and MDS were separately analyzed, the
donor G/G or A/G genotypes remained statistically significant for
a better OS in AML patients (58% vs. 45%; Fig. 1B), and had a
tendency to be related to a better OS in MDS patients (58% vs.
37%; Fig. 1C). In patients with lymphoid malignancies consisting
of ALL and ML, the donor granzyme B genotype had no
significant effects on transplant outcomes (Table 3). This was true
even when ALL and ML were separately analyzed (data not
shown).
Multivariate analysis
All of the factors found to be significant in the univariate
analyses were included in the model. In patients with myeloid
malignancies, the G/G or A/G genotype in donors were
statistically significant in the multivariate analyses for better OS
(adjusted hazard ratio [HR], 0.60; 95% confidence interval [CI],
0.41–0.89; P=0.01; Table 4) and TRM (adjusted HR, 0.45; 95%
CI, 0.25–0.80; P=0.01) when adjusted for the other factors in the
models. Despite not evident in the univariate analysis, the
multivariate analysis revealed the donor granzyme B G/G or
AG genotype was associated with lower incidence of chronic
GVHD (adjusted HR, 0.61; 95% CI, 0.37–0.99; P=0.05;
Table 5). In the independent analyses for AML patients and
MDS patients, beneficial effects on OS by the donor G/G or A/G
genotype were also found, which was close to being significant in
both the AML patients (adjusted HR, 0.68; 95% CI, 0.42–1.09;
P=0.10) and the MDS patients (adjusted HR, 0.61; 95% CI,
0.35–1.08; P=0.09). In addition, the recipient G/G or A/G
genotype was associated with a significantly better OS (adjusted
HR, 0.68; 95% CI, 0.47–0.99; P=0.05) and a trend toward a
reduced TRM (adjusted HR, 0.61; 95% CI, 0.35–1.06; P=0.08).
The difference between the donor G/G and A/G genotype did
not reach statistical significance in relation to transplant outcomes
(data not shown). The granzyme B genotype did not significantly
influence the transplant outcomes in patients with lymphoid
malignancies.
Discussion
The current study showed that the granzyme B G/G or A/G
genotype at rs8192917 (2364A.G) in the donor side representing
the triple variant RAH granzyme B was associated with a
significantly better OS and TRM compared to the granzyme A/A
genotype, corresponding to wild type QPY granzyme B, for
patients with myeloid malignancies receiving HLA-matched
unrelated BMT through the JMDP. The G/G or A/G genotypes
in the recipient also significantly improved the OS, as well the
TRM, although to a lesser extent. This is the first report to show
that the granzyme B polymorphism affects transplant outcomes.
The beneficial effects of the G/G or A/G genotype were absent
in patients with lymphoid malignancies, irrespective of whether it
was ALL or ML. A possible explanation for this may be that ALL
and ML cells express the apoptosis inhibitor Bcl-2[46] and the
endogenous inhibitor of granzyme B, proteinase inhibitor 9 (PI-
9).[47,48,49,50] The expression of these two factors by malignant
lymphoid cells may protect them from granzyme B-induced
apoptosis and proteolysis[46,48] and might thus negate the
differential effects of the different granzyme B genotypes.
Based on the traditional view that the triple-mutated granzyme
B has an impaired pro-apoptotic function, it was expected that the
presence of the RAH variant would predict an adverse clinical
outcomes after HSCT, namely poor survival or an increased
relapse rate. The results presented here, however, do not support
that assumption. The mechanisms by which the mutant granzyme
B genotype improved transplant outcomes remain unclear. This
may be due, in part, because the reports on the biochemical and
physiological properties of the triple variant RAH granzyme B are
still controversial.
Although an initial study[31] reported that RAH granzyme B
was unable to induce apoptosis in tumor cell lines, it was later
Table 3. The results of the univariate analysis of the association of the Granzyme B genotype with clinical outcomes after
transplantation.
Variable No.
5-year
OS P
5-year
TRM P
5-year
relapse P
II-IV acute
GVHD P
Chronic
GVHD P
Myeloid malignancy 353
Recipient Granzyme B genotype
A/G or G/G 139 52% 0.13 21% 0.17 33% 0.71 25% 0.23 40% 0.14
A/A 214 46% 26% 33% 31% 49%
Donor Granzyme B genotype
A/G or G/G 141 58% 0.01 20% 0.21 27% 0.10 28% 0.72 47% 0.79
A/A 212 42% 26% 37% 30% 45%
Lymphoid malignancy 260
Recipient Granzyme B genotype
A/G or G/G 93 48% 0.14 24% 0.26 35% 0.97 35% 0.66 31% 0.44
A/A 167 43% 26% 34% 33% 36%
Donor Granzyme B genotype
A/G or G/G 80 43% 0.93 29% 0.60 33% 0.78 34% 0.88 32% 0.49
A/A 180 46% 24% 35% 34% 36%
Abbreviations: OS, overall survival; TRM, Transplant-related mortality.
doi:10.1371/journal.pone.0023827.t003
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activity.[34] In addition to the classical role of granzyme B in
mediating apoptosis within target cells by NK cells and CTLs,
increasing evidence shows that extracellular granzyme B also has
alternative functions, including extracellular matrix remodeling,
immunosuppressive and cytokine-like effects.[18,19,24,51,52] A
recent report[19] showed that human DCs abundantly secrete
granzyme B, which can suppress T-cell expansion. Another report
revealed a pivotal function of granzyme B in immunosuppression
directed by regulatory T cells, leading to promotion of tumor
escape.[52] In addition, extracellular granzyme B potentially
induces apoptosis in various organs and tissues, thus leading to
chronic inflammatory, autoimmune, and degenerative diseas-
es.[18,24] In line with these observations, it is plausible that in
patients receiving HSCT, extracellular granzyme B could
contribute to significant effects, such as modulation of T-cell
functions and organ damage, because high serum levels of
extracellular granzyme B have been reported in HSCT recipi-
ents.[29]
Based on the results presented herein, it may therefore be
reasonable to hypothesize that the granzyme B variants have
differential biochemical properties whose biological consequences
are more relevant on the non-classical functions exerted by the
extracellular granzyme B. The analysis of patient serum may offer
useful information on this issue, although these samples were not
available for the present study. The fact that functional granzyme
B is also secreted by nonhematopoietic cells, including keratino-
cytes, chondrocytes, and smooth muscle cells[18,53] may explain
the findings that granzyme B variants in the recipient side, in
addition to that in the donor side, had an impact on the transplant
outcomes. Furthermore, this finding supports the view that the
presence of the triple-mutated Granzyme B is indeed responsible
for the beneficial effect in HSCT for myeloid malignancies.
The effects of the granzyme B G/G or A/G genotype on the
reduced TRM in patients with myeloid malignancies might be a
consequence of increased resistance to infections in these
recipients. This hypothesis, although attractive, is highly specula-
tive and is not supported by the present study because of the
unavailability of data on the causes of infections in this cohort.
Further studies will be needed to clarify whether the granzyme B
genotypes can differentially affect the responses of patients against
infections.
Two recent reports have described a significant correlation
between disease susceptibility and the RAH/QPY polymorphism in
the granzyme B gene. The wild type QPY genotype was associated
with an increased incidence of Epstein-Barr-virus-associated
Table 4. The results of a multivariate analysis of the association of the Granzyme B genotype with the clinical outcomes after
transplantation.
Variable OS TRM Relapse
Adjusted
HR 95% CI P
Adjusted
HR 95% CI P
Adjusted
HR 95% CI P
Myeloid malignancy
Recipient Granzyme B genotype, G/G or A/G 0.68 0.47–0.99 0.05 0.61 0.35–1.06 0.08 0.99 0.65–1.51 0.97
Donor Granzyme B genotype, G/G or A/G 0.60 0.41–0.89 0.01 0.45 0.25–0.80 0.01 0.75 0.48–1.15 0.19
Lymphoid malignancy
Recipient Granzyme B genotype, G/G or A/G 0.99 0.60–1.57 0.96 0.93 0.44–1.96 0.84 1.40 0.84–2.34 0.20
Donor Granzyme B genotype, G/G or A/G 0.72 0.43–1.28 0.23 0.84 0.32–2.22 0.72 0.87 0.49–1.56 0.65
doi:10.1371/journal.pone.0023827.t004
Figure 1. The Kaplan-Meier analysis of OS after BMT according
to the donor granzyme B genotype in patients with myeloid
malignancies (A), AML (B), and MDS (C).
doi:10.1371/journal.pone.0023827.g001
Granzyme B Variants and Transplant Outcomes
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23827hemophagocytic lymphohistiocytosis (HLH) in children.[32] Con-
versely, a subsequent study reported an association of the mutant
RAH genotype with the incidence of breast cancer.[33] However,
to link the genetic susceptibility of granzyme B to disease based on
thepresented data is difficult,because no patient developedHLHor
breast cancer following HSCT in the current cohort.
In conclusion, the present data suggest that the granzyme B
polymorphism may affect the prognosis after BMT from an
unrelated donor, and therefore, the granzyme B genotyping in
transplant donors and recipients may provide opportunities to
choose an ideal donor. However, care should be made in drawing
conclusions, because the number of patients evaluated in the
present study is limited. Experimental evidence is also required to
substantiate the effects of extracellular granzyme B according to
the polymorphism on organ and tissue damage. Further studies
are warranted to ascertain whether the findings of this study can
be extended to other disease groups, other stem cell sources, or
HLA-mismatched transplantation, as well as to validate the
present data.
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